Physician profile
John E Lattin
NPI 1275573743
$374.20
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $89.45 · 2021: $74.43 · 2022: $17.79.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $64.19 | 2019-2022 | |
| Glaxosmithkline, LLC. | $58.56 | 2019-2020 | |
| Sanofi Pasteur INC. | $57.92 | 2019-2021 | |
| Kaleo, INC. | $41.30 | 2019 | |
| Merck Sharp & Dohme LLC | $40.29 | 2019-2021 | |
| Sobi, INC | $39.83 | 2019 | |
| Boston Scientific Corporation | $26.70 | 2020-2021 | |
| Hologic Sales and Service, LLC | $18.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.31 | 2019 | |
| Abbvie INC. | $12.11 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lattin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.